CHOK1SV Cells being processed

Industry-Leading Technologies Combined

A new host cell line for the production of recombinant antibodies has been developed through close collaboration between Lonza and BioWa.  The new cell line, Potelligent® CHOK1SV, combines the advantages of Lonza’s proprietary GS Gene Expression System™ with the power of BioWa’s engineered glycosylation technology.

Scientists at Kyowa Hakko Kogyo Co. Ltd. (now, Kyowa Hakko Kirin Co., Ltd.) demonstrated that an antibody with a reduced fucose content in glycan moieties exhibited much higher antibody dependent cellular cytotoxicity (ADCC) activity compared to a normally fucosylated antibody. They confirmed that the mechanism behind the enhanced ADCC of a low / no-fucose antibody was its increased affinity to FcγRIIIa (CD16), the major Fc receptor for ADCC in humans. A cell line with knockout of both alleles for the gene responsible for fucose addition (α1,6-fucosyltransferase; FUT8) can take advantage of this phenomenon, producing Potelligent® mAbs with enhanced ADCC activity.

Creation of this new host cell line that combines the powerful Potelligent® Technology with Lonza’s pre-eminent host cell line, CHOK1SV, is significant advancement in gene expression technology.  An FUT8 double gene knock out variant of CHOK1SV has therefore been developed for therapeutic protein expression. This new host cell line has been called Potelligent® CHOK1SV Cell Line. 

As with traditional CHOK1SV, Potelligent® CHOK1SV grows in single cell suspension culture and in chemically defined, animal component-free media. Both the Potelligent® CHOK1SV host cell line and recombinant cell lines derived from Potelligent® CHOK1SV exhibit good growth characteristics as shown below.

Download our Potelligent® CHOK1SV Brochure  for more information.

 
Figure 1 and 2:  Examples of growth of Potelligent® CHOK1SV derived cell lines at routine subculture.